South Korea
· Delayed Price · Currency is KRW Daewon Pharmaceutical Statistics
Total Valuation
Daewon Pharmaceutical has a market cap or net worth of KRW 298.57 billion. The enterprise value is 427.20 billion.
| Market Cap | 298.57B |
| Enterprise Value | 427.20B |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Daewon Pharmaceutical has 21.43 million shares outstanding. The number of shares has increased by 0.14% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 21.43M |
| Shares Change (YoY) | +0.14% |
| Shares Change (QoQ) | +2.19% |
| Owned by Insiders (%) | 38.80% |
| Owned by Institutions (%) | 12.97% |
| Float | 12.84M |
Valuation Ratios
The trailing PE ratio is 18.42 and the forward PE ratio is 8.12. Daewon Pharmaceutical's PEG ratio is 0.46.
| PE Ratio | 18.42 |
| Forward PE | 8.12 |
| PS Ratio | 0.50 |
| PB Ratio | 1.07 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.46 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.33, with an EV/FCF ratio of -30.60.
| EV / Earnings | 26.67 |
| EV / Sales | 0.72 |
| EV / EBITDA | 8.33 |
| EV / EBIT | 13.51 |
| EV / FCF | -30.60 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.65.
| Current Ratio | 1.27 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | 3.74 |
| Debt / FCF | -13.59 |
| Interest Coverage | 3.59 |
Financial Efficiency
Return on equity (ROE) is 4.69% and return on invested capital (ROIC) is 4.49%.
| Return on Equity (ROE) | 4.69% |
| Return on Assets (ROA) | 3.61% |
| Return on Capital (ROIC) | 4.49% |
| Revenue Per Employee | 471.38M |
| Profits Per Employee | 12.71M |
| Employee Count | 1,260 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 2.92 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.43% in the last 52 weeks. The beta is 0.42, so Daewon Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -11.43% |
| 50-Day Moving Average | 14,458.60 |
| 200-Day Moving Average | 14,877.00 |
| Relative Strength Index (RSI) | 41.17 |
| Average Volume (20 Days) | 78,960 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daewon Pharmaceutical had revenue of KRW 593.94 billion and earned 16.02 billion in profits. Earnings per share was 756.15.
| Revenue | 593.94B |
| Gross Profit | 288.61B |
| Operating Income | 31.09B |
| Pretax Income | 19.15B |
| Net Income | 16.02B |
| EBITDA | 50.75B |
| EBIT | 31.09B |
| Earnings Per Share (EPS) | 756.15 |
Balance Sheet
The company has 71.78 billion in cash and 189.73 billion in debt, giving a net cash position of -117.95 billion or -5,503.12 per share.
| Cash & Cash Equivalents | 71.78B |
| Total Debt | 189.73B |
| Net Cash | -117.95B |
| Net Cash Per Share | -5,503.12 |
| Equity (Book Value) | 289.71B |
| Book Value Per Share | 13,018.52 |
| Working Capital | 55.45B |
Cash Flow
In the last 12 months, operating cash flow was 23.97 billion and capital expenditures -37.94 billion, giving a free cash flow of -13.96 billion.
| Operating Cash Flow | 23.97B |
| Capital Expenditures | -37.94B |
| Free Cash Flow | -13.96B |
| FCF Per Share | -651.45 |
Margins
Gross margin is 48.59%, with operating and profit margins of 5.23% and 2.70%.
| Gross Margin | 48.59% |
| Operating Margin | 5.23% |
| Pretax Margin | 3.22% |
| Profit Margin | 2.70% |
| EBITDA Margin | 8.54% |
| EBIT Margin | 5.23% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 300.00, which amounts to a dividend yield of 2.15%.
| Dividend Per Share | 300.00 |
| Dividend Yield | 2.15% |
| Dividend Growth (YoY) | -14.29% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 39.70% |
| Buyback Yield | -0.14% |
| Shareholder Yield | 2.01% |
| Earnings Yield | 5.43% |
| FCF Yield | -4.68% |
Stock Splits
The last stock split was on March 7, 2022. It was a forward split with a ratio of 1.03.
| Last Split Date | Mar 7, 2022 |
| Split Type | Forward |
| Split Ratio | 1.03 |
Scores
Daewon Pharmaceutical has an Altman Z-Score of 2.52. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.52 |
| Piotroski F-Score | n/a |